Allogeneic hematopoietic cell transplantation (HCT) following reduced-intensity conditioning in patients with acute leukemias

Critical Reviews in Oncology/Hematology

Volumn 56, Issue 2, 2005, Pages 275-281

  Niederwieser, Dietger ^a   Gentilini, Chiara ^a   Hegenbart, Ute ^a   Lange, Thoralf ^a   Becker, Cornelia ^a   Wang, Song Yau ^a   Bartsch, Kristina ^a   Pönisch, Wolfram ^a   Raida, Martin ^a   Al Ali, Haifa ^a  

^a UNIVERSITY OF LEIPZIG   (Germany)

Author keywords

Allogeneic hematopoietic cell transplants; Donor chimerism; Graft versus leukemia; Reduced intensity conditioning

Indexed keywords

ALKYLATING AGENT; ANTINEOPLASTIC AGENT; BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTARABINE; ETOPOSIDE; FLUDARABINE; IDARUBICIN; IMMUNOSUPPRESSIVE AGENT; MELPHALAN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PURINE DERIVATIVE; THYMOCYTE ANTIBODY;

ACUTE LEUKEMIA; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CHIMERA; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; HUMAN; MORTALITY; NONHUMAN; RELAPSE; REMISSION; REVIEW; WHOLE BODY RADIATION;

AGE FACTORS; AGED; GRAFT SURVIVAL; GRAFT VS LEUKEMIA EFFECT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA, LYMPHOCYTIC, ACUTE; LEUKEMIA, MYELOCYTIC, ACUTE; MIDDLE AGED; TRANSPLANTATION CHIMERA; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS;

EID: 27644596555     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2005.03.016     Document Type: Review

References (33)

1. R.A. Zittoun, F. Mandelli, R. Willemze, T. De Witte, B. Labar, and L. Resegotti Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in AML New Engl J Med 332 4 2003 217 223
2. W. Hiddemann, W. Kern, C. Schoch, C. Fonatsch, A. Heinecke, and B. Wörmann Management of acute myeloid leukemia in elderly patients J Clin Oncol 17 11 1999 3569 3576
3. A. Burnett, A. Goldstone, and R. Stevens Randomised comparison of addition of autologous bone marrow transplantation to intensive chemotherapy for acute myeloid leukaemia in first remission: results of MRC AML 10 trial Lancet 351 1998 700 708
4. T. Buchner, W. Hiddemann, B. Wormann, H. Loffler, W. Gassmann, and T. Haferlach Double induction strategy for acute myeloid leukemia: the effect of high-dose cytarabine with mitoxantrone instead of standard-dose cytarabine with daunorubicin and 6-thioguanine Blood 93 12 1999 4116 4124
5. B. Lowenberg, J.R. Downing, and A. Burnett Acute myeloid leukemia New Engl J Med 341 14 1995 1051 1062
6. J.Y. Cahn, M. Labopin, J. Sierra, D. Blaise, D. Reiffers, and A. Ferrant No impact of high-dose cytarabine on the outcome of patients transplanted for acute myeloblastic leukaemia in first remission Br J Haematol 110 2 2000 308 314
7. P. Anderlini, H.M. Ghaddar, T.L. Smith, S. Pierce, H.M. Kantarjian, and S. O'Brien Factors predicting complete remission and subsequent disease-free survival after a second course of induction therapy in patients with acute myelogenous leukemia resistant to the first Leukemia 10 6 1996 964 969
8. E.D. Thomas, C.D. Buckner, M. Banaji, R.A. Clift, A. Fefer, and N. Flournoy One hundred patients with acute leukemia treated by chemotherapy, total body irradiation, and allogeneic marrow transplantation Blood 49 1977 511 533
9. F.R. Appelbaum, L.D. Fisher, and E.D. Thomas Chemotherapy vs. marrow transplantation for adults with acute nonlymphocytic leukemia: a five-year follow-up Blood 72 1988 179 184
10. J.O. Armitage Bone marrow transplantation New Engl J Med 330 1994 827 838
11. P.L. Weiden, N. Flournoy, E.D. Thomas, R.L. Prentice, A. Fefer, and C.D. Buckner Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts New Engl J Med 300 1979 1068 1073
12. H.-J. Kolb, A. Schattenberg, J.M. Goldman, B. Hertenstein, N. Jacobsen, and W. Arcese Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients Blood 86 5 1995 2041 2050
13. S. Slavin, E. Naparstek, A. Nagler, A. Ackerstein, S. Samuel, and J. Kapelushink Allogeneic cell therapy with donor peripheral blood cells and recombinant human interleukin-2 to treat leukemia relapse after allogeneic bone marrow transplantation Blood 87 6 1996 2195 2204
14. S. Slavin, A. Nagler, E. Naparstek, Y. Kapelushnik, M. Aker, and G. Cividalli Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases Blood 91 3 1998 756 763
15. S. Giralt, P.F. Thall, I. Khouri, X. Wang, I. Braunschweig, and C. Ippoliti Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation Blood 97 3 2001 631 637
16. A. Nagler, M. Aker, R. Or, E. Naparstek, G. Varadi, and C. Brautbar Low-intensity conditioning is sufficient to ensure engraftment in matched unrelated bone marrow transplantation Exp Haematol 29 2001 362 370
17. R. Chakraverty, K. Peggs, R. Chopra, D.W. Milligan, D. Kottaridis, and S. Verfueth Limiting transplantation-related mortality following unrelated donor stem cell transplantation by using a nonmyeloablative conditioning regimen Blood 99 2002 1071 1078
18. R. Martino, M.D. Caballero, J.A.P. Simon, C. Canals, C. Solano, and A. Urbano Ispizua Evidence for a graft-versus-leukemia effect after allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning in acute myelogenous leukemia and myelodysplastic syndromes Blood 100 6 2002 2243 2245
19. H.G. Sayer, M. Kröger, J. Beyer, M. Kiehl, S.A. Klein, and K. Schaefer-Eckart Reduced intensity conditioning for allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia: disease status by marrow blasts is the strongest prognostic factor Bone Marrow Transplant 31 2003 1089 1095
20. H. Bertz, K. Potthoff, and J. Finke Allogeneic stem-cell transplantation from related and unrelated donors in older patients with myeloid leukemia J Clin Oncol 21 8 2003 1480 1484
21. N. Kröger, M. Bornhäuser, G. Ehninger, R. Schwerdtfeger, H. Biersack, and H.G. Sayer Allogeneic stem cell transplantation after a fludarabine/busulfan-based reduced-intensity conditioning in patients with myelodysplastic syndrome or secondary acute myeloid leukemia Ann Hematol 83 2003 336 342
22. D.C. Taussig, A.J. Davies, J.D. Cavenagh, H. Oakervee, D. Syndercombe-Court, and S. Kelsey Durable remissions of MDS and AML after reduced-intensity allografting J Clin Oncol 21 16 2003 3060 3065
23. R. Wong, S.A. Giralt, T. Martin, D.R. Couriel, A. Anagnostopoulos, and C. Hosing Reduced-intensity conditioning for unrelated donor hematopoietic stem cell transplantation as treatment for myeloid malignancies in patients older than 55 years Blood 102 8 2003 3052 3059
24. R. Storb, C. Yu, J.L. Wagner, J. Deeg, R.A. Nash, and H.P. Kiem Stable mixed hematopoietic chimerism in DLA identical littermate dogs given sublethal total body irradiation before and pharmacological immunosuppression after marrow transplantation Blood 89 1997 3048 3054
25. A. Bacigalupo Third EBMT/AMGEN Workshop on Reduced-Intensity Conditioning Allogeneic Haemopoietic Stem Cell Transplants (RIC-HSCT), and Panel Consensus Bone Marrow Transplant 33 2004 691 696
26. P.A. McSweeney, D. Niederwieser, J.A. Shizuru, B.M. Sandmaier, A.-J. Molina, and D.G. Maloney Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects Blood 97 2001 3390 3400
27. D. Niederwieser, M. Maris, J.A. Shizuru, E. Petersdorf, U. Hegenbart, and B. Sandmaier Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors and postgrafting immunosuppression with cyclosporine and mycophenolate mofetil (MMF) can induce durable complete chimerism and sustained remissions in patients with hematological diseases Blood 101 2003 1620 1629
28. C. Faucher, M. Mohty, N. Vey, B. Gaugler, K. Bilger, and M.-J. Moziconnacci Bone marrow as stem cell source for allogeneic HLA-identical sibling transplantation following reduced-intensity preparative regimen Exp Hematol 31 2003 873 880
29. M. Bornhäuser, C. Thiede, U. Platzbecker, A. Jenke, A. Helwig, and R. Plettig Dose-reduced conditioning and allogeneic hematopoietic stem cell transplantation from unrelated donors in 42 patients Clin Cancer Res 7 2001 2254 2262
30. R.F. Schlenk, F. Hartmann, M. Hensel, W. Jung, R. Weber-Nordt, and A. Gabler Less intense conditioning with fludarabine, cyclophosphamide, idarubicin and etoposide (FCIE) followed by allogeneic unselected peripheral blood stem cell transplantation in elderly patients with leukemia Leukemia 16 2002 581 586
31. Hegenbart U, Sandmaier B, Maris M, Stuart MJ, Greinix H, Cordonnier C, et al. Low dose irradiation based conditioning followed by postgrafting immunosuppression with cyclosporine and MMF for related and unrelated donor hematopoietic cell transplantation as treatment for acute myelogenous leukemia, J Clin Oncol 2005; submitted for publication.
32. L.C. Feinstein, B.M. Sandmaier, U. Hegenbart, P.A. McSweeney, D.G. Maloney, and T.A. Gooley Non-myeloablative allogafting from human leucocyte antigen-identical sibling donors for treatment of acute myeloid leukaemia in first complete remission Br J Haematology 120 2003 281 288
33. R. Arnold, G. Massenkeil, M. Bornhäuser, G. Ehninger, D.W. Beelen, and A.A. Fauser Nonmyeloablative stem cell transplantation in adults with high-risk ALL may be effective in early but not in advanced disease Leukemia 16 2002 2423 2428